SSII Quote, Financials, Valuation and Earnings

Intuitive Surgical has a net margin of -110.95% compared to SS Innovations International's net margin of 30.99%. SS Innovations International's return on equity of -76.16% beat Intuitive Surgical's return on equity of 15.82%.

SS Innovations International has a consensus price target of --, signalling downside risk potential of --. On the other hand Intuitive Surgical has an analysts' consensus of $581.45 which suggests that it could grow by 12.12%. Given that Intuitive Surgical has higher upside potential than SS Innovations International, analysts believe Intuitive Surgical is more attractive than SS Innovations International.

SS Innovations International has a beta of -68.829, which suggesting that the stock is 6982.93% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

SS Innovations International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SS Innovations International pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

SS Innovations International quarterly revenues are $5.1M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. SS Innovations International's net income of -$5.7M is lower than Intuitive Surgical's net income of $698.4M. Notably, SS Innovations International's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 76.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SS Innovations International is 65.55x versus 21.60x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -110.95% compared to SS Innovations International's net margin of -2201.34%. SS Innovations International's return on equity of -76.16% beat VolitionRX's return on equity of --.

SS Innovations International has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 335.56%. Given that VolitionRX has higher upside potential than SS Innovations International, analysts believe VolitionRX is more attractive than SS Innovations International.

SS Innovations International has a beta of -68.829, which suggesting that the stock is 6982.93% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

SS Innovations International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SS Innovations International pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

SS Innovations International quarterly revenues are $5.1M, which are larger than VolitionRX quarterly revenues of $246.4K. SS Innovations International's net income of -$5.7M is lower than VolitionRX's net income of -$5.4M. Notably, SS Innovations International's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SS Innovations International is 65.55x versus 46.52x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -110.95% compared to SS Innovations International's net margin of -2828.67%. SS Innovations International's return on equity of -76.16% beat Catheter Precision's return on equity of -137.84%.

SS Innovations International has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 762.07%. Given that Catheter Precision has higher upside potential than SS Innovations International, analysts believe Catheter Precision is more attractive than SS Innovations International.

SS Innovations International has a beta of -68.829, which suggesting that the stock is 6982.93% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

SS Innovations International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SS Innovations International pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

SS Innovations International quarterly revenues are $5.1M, which are larger than Catheter Precision quarterly revenues of $143K. SS Innovations International's net income of -$5.7M is lower than Catheter Precision's net income of -$4M. Notably, SS Innovations International's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SS Innovations International is 65.55x versus 2.66x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -110.95% compared to SS Innovations International's net margin of 0.18%. SS Innovations International's return on equity of -76.16% beat Xtant Medical Holdings's return on equity of -26.62%.

SS Innovations International has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 178.26%. Given that Xtant Medical Holdings has higher upside potential than SS Innovations International, analysts believe Xtant Medical Holdings is more attractive than SS Innovations International.

SS Innovations International has a beta of -68.829, which suggesting that the stock is 6982.93% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

SS Innovations International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SS Innovations International pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

SS Innovations International quarterly revenues are $5.1M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. SS Innovations International's net income of -$5.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, SS Innovations International's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SS Innovations International is 65.55x versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.